Success Story: Aagami secures funding for US client developing First-in-Class Non-Opioid Analgesic for Pain Relief We are pleased to announce tha...
Published : 22 Apr 2023
Read MoreAagami has been appointed as consultant by another Korean client which has developed world’s first digital monitoring and management solution for Th...
Published : 10 Apr 2023
Read MoreAagami has a new client. This time it is an Award-winning New York biotech specializing in molecular engineering, RNAi and CRISPR/Cas9 technologi...
Published : 07 Apr 2023
Read MoreAagami CEO, Dinesh Jain, is participating in the 2023 BIO International Convention which will be held in Boston (June 5-8, 2023). This Annual eve...
Published : 29 Mar 2023
Read MoreWe are glad to inform that Aagami CEO Dinesh Jain will be attending DCAT Week 2023 in person from MARCH 20 to 23 in New York City. If you or...
Published : 24 Feb 2023
Read MoreA Canada-US-Hongkong based biotech has appointed Aagami to support their investment and partnering needs for their ‘Single (monovalent) vaccine for ...
Published : 23 Feb 2023
Read MoreAagami completed a very fruitful JPM week and Biotech Showcase 2023 in San Francisco (January 9–11) with over 40 one-on-one strategic meetings with ...
Published : 16 Jan 2023
Read MoreAagami CEO Dinesh Jain and VP Godwyn Francis completed a very fruitful business trip to Republic of Korea in December 2022. Aagami was a par...
Published : 15 Dec 2022
Read MoreAagami are glad to announce that their Japanese client has given a new assignment, to seek partnerships for one more asset in their pipeline. Aagami a...
Published : 22 Nov 2022
Read MoreBio2Device Group (B2DG), CA have organized an event where Aagami CEO Dinesh Jain will be speaking on "How To Do Cross Border Partnering in Lifescience...
Published : 14 Nov 2022
Read More